Address
304 North Cardinal
St. Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
Address
304 North Cardinal
St. Dorchester Center, MA 02124
Work Hours
Monday to Friday: 7AM - 7PM
Weekend: 10AM - 5PM
NAD+ and MOTS-C get grouped as "longevity compounds," but they're fundamentally different tools — a coenzyme versus a mitochondrial peptide. This guide compares their mechanisms, evidence gaps, regulatory status, and practical differences side by side, including the systematic review that found zero completed outcomes trials for injectable NAD+.
MOTS-C is unlike anything else in this guide series — a peptide encoded in mitochondrial DNA, discovered in 2015. This guide covers its AMPK-activation mechanism, the real story behind the CB4211 analog often confused with it, why cycling matters, and the practical dosing math for a genuinely novel compound.
NAD+ IV therapy is available at thousands of clinics worldwide — and a 2025 systematic review found zero completed outcomes trials for injectable use, for any of the claims it's marketed on. This guide covers what's actually been shown, the real mechanism behind the flush, and how it compares to oral precursors.